Company profile: Halozyme
1.1 - Company Overview
Company description
- Provider of extracellular matrix-targeting products and drug delivery technologies, including ENHANZE to enable subcutaneous delivery and reduce administration time vs hours-long IV infusions; HYLENEX recombinant hyaluronidase to aid dispersion and absorption of injected drugs/fluids; XYOSTED testosterone enanthate for replacement therapy; and auto-injector platforms for subcutaneous/intramuscular use, with a partner pipeline in five approved therapeutics.
Products and services
- ENHANZE®: Drug delivery technology facilitating subcutaneous administration of injected drugs and fluids, potentially reducing treatment from hours-long IV infusions to minutes-long injections
- Subcutaneous-capable
- Auto-Injector Technology: A range of auto-injectors engineered for subcutaneous and intramuscular use to address patient and therapeutic needs, enabling consistent self-administration
- Dual-route
- HYLENEX® recombinant: Hyaluronidase human injection used to facilitate dispersion and absorption of other injected drugs or fluids for enhanced delivery
- Recombinant
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Halozyme
Xcell Biosciences
HQ: United States
Website
- Description: Provider of a next-generation development and manufacturing platform for enhanced cell therapy performance, offering AVATAR Foundry, an automated closed system for autologous cell therapy production (in beta); AVATAR System, an incubator that fine-tunes oxygen and pressure to mimic in vivo; AVATAR AI, software using machine learning for drug behavior prediction and potency assay development; and AVATAR AD, a four-instrument system for assay development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcell Biosciences company profile →
Pelican Therapeutics
HQ: United States
Website
- Description: Provider of next-generation TNF-based immunotherapy biologic agents, focused on developing and commercializing monoclonal antibody and fusion protein therapies designed to activate the immune system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pelican Therapeutics company profile →
Novacyt
HQ: France
Website
- Description: Provider of in vitro and molecular diagnostic tests and cellular diagnostics, with a growing portfolio in cancer and infectious disease, offering diagnostics product development, commercialisation, and contract design and manufacturing via Primerdesign and Lab21 Products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novacyt company profile →
MiNK Therapeutics
HQ: United States
Website
- Description: Provider of allogeneic invariant natural killer T (iNKT) cell therapies and immune technologies, including AGENT-797 for solid tumors and severe ARDS; native iNKT therapies; engineered iNKT therapies with CARs and bispecific engagers; and platforms (CARDIS and IgG-based bispecific iNKT cell engagers) for discovering, optimizing, and developing targeted cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MiNK Therapeutics company profile →
ESSA Pharma
HQ: Canada
Website
- Description: Provider of small molecule drugs for cancer treatment, with a focus on advanced prostate cancer, developing therapies that selectively block the N-terminal domain of the androgen receptor, a target required for the growth and survival of most prostate cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ESSA Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Halozyme
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Halozyme
2.2 - Growth funds investing in similar companies to Halozyme
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Halozyme
4.2 - Public trading comparable groups for Halozyme
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →